443 related articles for article (PubMed ID: 30487231)
21. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15.
Yamashita S; Kiyosue A; Maheux P; Mena-Madrazo J; Lesogor A; Shao Q; Tamaki Y; Nakamura H; Akahori M; Kajinami K
J Atheroscler Thromb; 2024 Jun; 31(6):876-903. PubMed ID: 38220186
[TBL] [Abstract][Full Text] [Related]
23. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
24. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
[TBL] [Abstract][Full Text] [Related]
25. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
26. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
27. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
[TBL] [Abstract][Full Text] [Related]
28. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou S; Ray KK
Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
[TBL] [Abstract][Full Text] [Related]
29. An update on inclisiran for the treatment of elevated LDL cholesterol.
Barkas F; Ray K
Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
[TBL] [Abstract][Full Text] [Related]
30. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
[TBL] [Abstract][Full Text] [Related]
31. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
[TBL] [Abstract][Full Text] [Related]
32. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
[TBL] [Abstract][Full Text] [Related]
33. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142
[TBL] [Abstract][Full Text] [Related]
34. Inclisiran-New hope in the management of lipid disorders?
Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
[TBL] [Abstract][Full Text] [Related]
35. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
Leiter LA; Raal FJ; Schwartz GG; Koenig W; Ray KK; Landmesser U; Han J; Conde LG; Wright RS
Diabetes Obes Metab; 2024 Aug; 26(8):3223-3237. PubMed ID: 38757725
[TBL] [Abstract][Full Text] [Related]
36. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
Katsiki N; Vrablik M; Banach M; Gouni-Berthold I
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334
[TBL] [Abstract][Full Text] [Related]
37. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V
Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116
[TBL] [Abstract][Full Text] [Related]
38. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
39. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
40. Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia.
Sokolov V; Helmlinger G; Nilsson C; Zhudenkov K; Skrtic S; Hamrén B; Peskov K; Hurt-Camejo E; Jansson-Löfmark R
J Lipid Res; 2019 Sep; 60(9):1610-1621. PubMed ID: 31292220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
